With the discovery of specific RANK signals in osteoclasts, human IgG2 monoclonal antibodies, such as denosumab, have been used to inhibit osteoclast activity, prevent bone metastasis of solid tumors or SREs, and prolong the survival of patients with tumors, and they may, to a certain extent, prevent the incidence of breast cancer in patients at high risk [119,120]. Here, TNFRSF11A is linked to breast cancer.